ADMA
NASDAQ
$8.75
Adma Biologics Inc (ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $17 (+94.29%)
Market Cap
$2.02B
Revenue 5Y CAGR
+60.37%
Profit Margin
39.6%
Forward P/E
10.50
Price Chart
Valuation
Market Cap$2.02B
P/E12.42
Forward P/E10.50
P/S4.03
P/B5.33
Profitability
Total Revenue (TTM)$510M
Gross Profit (TTM)$312M
EBITDA$223M
Profit Margin39.6%
Operating Margin50.9%
EPS$0.70
Financial Health
Debt-to-Equity50.4%
Free Cash Flow Yield5.35%
Growth & Risk
Revenue 5Y CAGR+60.37%
Beta (5Y)1.16
Sharpe Ratio-1.08